# US 2023/0271950 A1 · Antibacterial picolinamide compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271950 A1
- Document ID: US20230271950A1
- Status: Published application
- Kind: A1
- Application number: 18/003,166
- Filed: 2021-06-28
- Published: 2023-08-31
- Earliest claimed: 2020-06-29
- Assignees: University of Notre Dame du Lac
- Applicants: University of Notre Dame Du Lac
- Inventors: Shahriar MOBASHERY; Mayland CHANG; Enrico SPERI
- Web page: https://patentgrep.com/patent/US20230271950A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61P 31/04: Antibacterial agents
- C07D 213/81: Amides; Imides
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Here we report the discovery of 2-(4-(3-(trifluoromethoxy)phenoxy)picolinamido)benzo[d]oxazole-5-carboxylate as an antibacterial with potent and selective activity against C. difficile. Its MIC50 and MIC90 values, documented across 101 strains of C. difficile, are 0.12 and 0.25 μg/mL, respectively. The compound is effective against C. difficile both at the logarithmic (vegetative) and stationary phases of growth. It targets cell-wall biosynthesis, as assessed both by macromolecular biosynthesis assays and by scanning-electron microscopy. Animals infected with a lethal dose of C. difficile and treated with compound 1 had better survival compared to treatment with vancomycin, which is the front-line antibiotic used for severe recurrent C. difficile infection.

## Claims

### Claim 1

A compound of Formula I:
or a salt thereof,
wherein
Het is
Q1 is O, absent, S, or NRw;
Q2 is CH or N;
each Rw is independently H, —(C1-C6)alkyl, or a protecting group;
Rx, Ry, and Rz are each independently H, halo, OH, CN, CO2H, NO2, —(C1-C6)alkyl, —CO2(C1-C6)alkyl, —O(C1-C6)alkyl, or —OC(═O)(C1-C6)alkyl;
R1 is ORa, SRa, halo, CN, NO2, —(C1-C6)alkyl, NRw, or heterocyclyl,
wherein each Ra is independently CF3, —(C1-C6)alkyl, —C(═O)(C1-C6)alkyl, or H;
R2 is OH, —O(C1-C6)alkyl, —O(C3-C6)cycloalkyl, or —CCH;
R3 is H, —(C1-C6)alkyl or —(C3-C6)cycloalkyl;
R4 is H, —(C1-C6)alkyl, or —C(═O)R5 wherein R5 is OH, N(CH3)2, —O(C1-C6)alkyl, or heterocyclyl;
Y1, Y2, Y3, and Y4 are each independently CH or N wherein at least one of Y1 to Y4 is N;
Z1 is O, N, S, or CH; and
Z2 is CH, O, or N;
wherein each (C1-C6)alkyl moiety is independently saturated or unsaturated and optionally substituted.

### Claim 2 (depends on 1)

The compound of claim 1 wherein Het is

### Claim 3 (depends on 2)

The compound of claim 2 wherein Q2 is CH.

### Claim 4 (depends on 2)

The compound of claim 2 wherein Rx, Ry, and Rz are H.

### Claim 5 (depends on 1)

The compound of claim 1 wherein Y1 is N, and Y2, Y3, and Y4 are CH.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R1 is OR.

### Claim 7 (depends on 1)

The compound of claim 1 wherein the compound is represented by Formula II:
or a salt thereof.

### Claim 8 (depends on 7)

The compound of claim 7 wherein Q1 is O.

### Claim 9 (depends on 7)

The compound of claim 7 wherein Ra is CF3.

### Claim 10 (depends on 7)

The compound of claim 7 wherein R2 is OH.

### Claim 11 (depends on 7)

The compound of claim 7 wherein the compound is 2-(4-(3-(trifluoromethoxy)phenoxy) picolinamido)benzo[d]oxazole-5-carboxylic acid (1):
or a salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable diluent, carrier, or excipient.

### Claim 13 (depends on 12)

The composition of claim 12 wherein the compound is 2-(4-(3-(trifluoromethoxy)phenoxy) picolinamido)benzo[d]oxazole-5-carboxylic acid (1).

### Claim 14 (depends on 1)

A method for treating a bacterial infection comprising administering to a subject in need thereof an effective antibacterial amount of a compound of claim 1 wherein the bacterial infection is thereby treated.

### Claim 15 (depends on 14)

The method of claim 14 wherein the bacterial infection is a Clostridioides difficile (C. difficile) infection.

### Claim 16 (depends on 15)

The method of claim 15 wherein the compound selectively inhibits the growth or proliferation of C. difficile.

### Claim 17 (depends on 16)

The method of claim 16 wherein a minimum concentration to inhibit the growth or proliferation of 50% of C. difficile (MIC50) is about 1 μg/mL or less.

### Claim 18 (depends on 16)

The method of claim 16 wherein an effective antibacterial amount of the compound administered as a single dose is about 50 mg/kg or less.

### Claim 19 (depends on 14)

The method of claim 14 wherein the compound is 2-(4-(3-(trifluoromethoxy)phenoxy) picolinamido)benzo[d]oxazole-5-carboxylic acid (1).

### Claim 20 (depends on 14)

The method of claim 14 wherein the compound inhibits peptidoglycan biosynthesis.
